Completed PHASE2 INTERVENTIONAL 5-arm NCT00937326

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Sponsor: GlaxoSmithKline

Conditions Diabetes Mellitus, Type 2

Interventions Placebo SRT2104

Updated 8 times since 2017 Last updated: May 2, 2018 Started: Aug 19, 2009 Primary completion: Sep 18, 2010 Completion: Sep 18, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetes Mellitus, Type 2 and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE2
May 2018 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — May 2018 [monthly]

Completed PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Sirtris, a GSK Company

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bacau, Romania , Balantonfured, Hungary , Barnaul, Russia , Birmingham, United Kingdom , Brăila, Romania , Buzău, Romania , Byala, Bulgaria , Cieszyn, Poland , Constanța, Romania , Dimitrovgrad, Bulgaria and 38 more locations